Kesimpta for multiple sclerosis (ofatumumab) “Monthly MS treatment, cared for end to end”
A once-monthly injection for adults with relapsing multiple sclerosis (MS), used at home with a pre-filled pen.
- 20 mg per injection
- 1x / month after 3 weekly starting doses
- Store at 2- 8 °C in the fridge
- 7 days max out of fridge, not above 30°C
For education only. Your doctor decides if Kesimpta is right for you. Always follow the leaflet in your pack.
How well Kesimpta works
In the ASCLEPIOS I and II trials, 1,882 adults with relapsing MS took Kesimpta or teriflunomide (an oral MS medicine) for up to 30 months.[3] Study 1 / Study 2:
- 51% / 58% fewer relapses per year
- 98% / 94% fewer active MRI lesions
- 82% / 85% fewer new or enlarging T2 lesions
- 34% lower risk of disability worsening
Kesimpta for multiple sclerosis at a glance
Kesimpta (ofatumumab) is a prescription B-cell therapy made by Novartis for adults with relapsing multiple sclerosis (MS). It is a 20 mg injection under the skin, given at weeks 0, 1 and 2 and then once a month, using a pre-filled pen at home. It is approved in the UAE.
| Used for | Adults with relapsing forms of MS: clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS ² |
| Generic name | ofatumumab |
| Medicine type | Human monoclonal antibody that targets CD20 (B-cell therapy)² |
| How it works | Binds to CD20 on B cells and breaks them down. The exact way it works in MS is not known.² |
| Form | 20 mg/0.4 mL single-dose pre-filled pen or syringe¹ |
| How often | Weeks 0, 1 and 2, then once a month from week 4¹ |
| Not approved for | Primary progressive MS, or anyone under 18² |
| Made by | Novartis² |
| Status in the UAE | Approved in the UAE. Prescription only.¹ᐟ⁷ |
Kesimpta delivery and support across the UAE
Al Thiqa delivers Kesimpta free across the UAE in cold-chain packaging, and supports you between doses with reminders, insurance approvals, and a pharmacist available 24/7.
- Free delivery: Cold-chain, to your door
- 24/7 pharmacist access: A clinical pharmacist, any time
- Dose reminders: Before every monthly dose
- Care coordination: We book your doctor visits
- Side-effect support: Advice when you need it
- Lab tests: Special rates on monitoring tests
- Home injection support: Additional fee
- Financial assistance: Where available
Kesimpta dosing schedule
Kesimpta is 20 mg injected under the skin: three starting doses at weeks 0, 1, and 2, no dose at week 3, then one dose every month from week 4.
- Week 0 – starting dose
- Week 1 – starting dose
- Week 2 – starting dose
- Week 3 – no dose
- Week 4 – first monthly dose
- Then – every month
The plan
- 20 mg under the skin each time.¹
- First injection under the guidance of a healthcare professional, then at home.²
Missed a dose?
- Starting dose (week 0, 1 or 2): talk to your doctor.
- Monthly dose: inject it as soon as possible. Do not wait for the next scheduled dose.
- After that, keep injections a month apart.²ᐟ⁵
How to use the Kesimpta Sensoready pen
- Take out of the fridge 15 to 30 min before.
- Liquid should be clear to slightly opalescent. Do not use if cloudy or has particles.
- Use within 5 min of removing the cap. Press firmly. You will hear 2 clicks. Hold until the green indicator fills the window and stops moving.
- Into a sharps container right away. Never in household trash.
Steps from the official Instructions for Use.² If the green indicator does not fill the window, the medicine has not been delivered: contact your healthcare provider.
Where to inject Kesimpta
Inject Kesimpta into the front of the thigh or the lower belly. Use the outer upper arm only if a caregiver or healthcare professional injects for you.
- 🟢 Front of thigh: the recommended site.
- 🟢 Lower belly: not within 2 inches (5 cm) of the navel.
- 🟣 Outer upper arm*: only if a caregiver or professional injects.
- 🔴 Avoid tender, bruised, red, scaly, or hard skin, moles, scars, and stretch marks.²
Before you start Kesimpta for multiple sclerosis
Before the first dose, you need blood tests for hepatitis B, immunoglobulins, and liver function. Live vaccines should be given at least 4 weeks before you start.
Tests and vaccines
- Hepatitis B, immunoglobulin, and liver tests.²
- Live vaccines at least 4 weeks before. Non-live at least 2 weeks before, when possible.¹
- Active infection? Treatment is delayed until it clears.²ᐟ⁶
- Tell your doctor about immune medicines, liver problems, recent vaccines, pregnancy plans, or breastfeeding.
Do not use if you have
- Active hepatitis B.
- Had an allergy to ofatumumab, or a life-threatening reaction to a Kesimpta injection.²
First-dose checklist
Kesimpta: before your first dose
- [ ] Blood tests done
- [ ] Vaccines checked with my doctor
- [ ] Insurance approval received
- [ ] Fridge space ready (2-8°C) and sharps container
- [ ] First injection booked
- [ ] Monthly reminder set
How to store Kesimpta in UAE heat
Store Kesimpta in the fridge at 2-8°C. It can stay out of the fridge for up to 7 days, but never above 30°C, a temperature UAE cars and balconies pass quickly in summer.
- In the fridge (2-8°C)
- Original box, away from light
- Do not freeze
- Do not shake
Out of the fridge
- Up to 7 days at room temperature, not above 30°C. Write the date on the box.
- If unused, return it to the fridge and use it within 7 days, or discard.²
- Pharmacist tip: in UAE heat, carry it in a cool bag and never leave it in a car.
Kesimpta side effects and when to call
The most common side effects of Kesimpta are colds, headache, flu-like reactions after injecting, and redness or pain where you inject.
Common
- Colds and other upper respiratory infections
- Headache
- Fever, chills, muscle pain or tiredness after injecting, mostly with the first dose and within 24 hours
- Redness, swelling, itching or pain where you inject¹
Call 998 for
- Trouble breathing, chest tightness, feeling faint, or swelling of the face, eyelids, lips, tongue, or throat.
Call your doctor for
- Infection: fever, chills, cough, sore throat, runny nose, body aches, or painful and frequent urination.
- Liver or hepatitis B: yellow skin or eyes, dark urine, nausea, vomiting, or feeling tired or weak.
- Nerve changes: weakness on one side of the body, loss of coordination, vision problems, or changes in thinking, memory or personality.²
Kesimpta in pregnancy and breastfeeding
- May lower B cells in an unborn baby.
- Use effective birth control during treatment and for 6 months after the last dose.¹
- Became pregnant? Tell your doctor right away. Breastfeeding or planning to? Talk to your doctor first.²
Sources
Last reviewed 18/11/2026
- Novartis. Kesimpta (ofatumumab) 20 mg Basic Succinct Statement, Version 2.1, effective 09-Aug-2023 (leaflet date Feb 2024). Published on the Novartis UAE healthcare professional site. Link
- Novartis. KESIMPTA US Prescribing Information, Medication Guide and Instructions for Use. Revised 4/2026 (current version). U.S. FDA. Link
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. doi:10.1056/NEJMoa1917246
- US Prescribing Information: OCREVUS (Genentech, revised 5/2026) Link; OCREVUS ZUNOVO (Genentech, revised 9/2026) Link; BRIUMVI (TG Therapeutics, revised 1/2026) Link
- Novartis. KESIMPTA patient website: Frequently Asked Questions. Link
- Novartis Pharmaceuticals UK. Kesimpta 20 mg pre-filled pen, Summary of Product Characteristics. Revised 24 September 2026. Link
- Novartis. Media release: EU approval of Kesimpta, 30 March 2021 (lists approval in the United Arab Emirates). Link
- Pardo G, Montalban X, Cohen J, et al. Ofatumumab treatment up to 8 years shows a favorable and consistent safety profile in people living with relapsing multiple sclerosis. American Academy of Neurology Annual Meeting, April 2026. Reported by NeurologyLive. Link
